Immune Landscape and Response to Oncolytic Virus-based Immunotherapy

Overview

Journal Front Med

Specialty General Medicine

Date 2024 Mar 7

PMID 38453818

Authors

Chaolong Lin

Wenzhong Teng

Yang Tian

Shaopeng Li

Ningshao Xia

Chenghao Huang

Affiliations

Soon will be listed here.

Abstract

Oncolytic virus (OV)-based immunotherapy has emerged as a promising strategy for cancer treatment, offering a unique potential to selectively target malignant cells while sparing normal tissues. However, the immunosuppressive nature of tumor microenvironment (TME) poses a substantial hurdle to the development of OVs as effective immunotherapeutic agents, as it restricts the activation and recruitment of immune cells. This review elucidates the potential of OV-based immunotherapy in modulating the immune landscape within the TME to overcome immune resistance and enhance antitumor immune responses. We examine the role of OVs in targeting specific immune cell populations, including dendritic cells, T cells, natural killer cells, and macrophages, and their ability to alter the TME by inhibiting angiogenesis and reducing tumor fibrosis. Additionally, we explore strategies to optimize OV-based drug delivery and improve the efficiency of OV-mediated immunotherapy. In conclusion, this review offers a concise and comprehensive synopsis of the current status and future prospects of OV-based immunotherapy, underscoring its remarkable potential as an effective immunotherapeutic agent for cancer treatment.

Citing Articles

Comparison of differences in immune cells and immune microenvironment among different kinds of oncolytic virus treatments.

Wu X, Fang S Front Immunol. 2024; 15:1494887.

PMID: 39588373 PMC: 11586384. DOI: 10.3389/fimmu.2024.1494887.

Murine colon cancer derived cells exhibit heterogeneous resistance profiles against an oncolytic virus.

Larrieux A, Sanjuan R Sci Rep. 2024; 14(1):27209.

PMID: 39516525 PMC: 11549347. DOI: 10.1038/s41598-024-78313-6.

Parainfluenza Virus 5 V Protein Blocks Interferon Gamma-Mediated Upregulation of NK Cell Inhibitory Ligands and Improves NK Cell Killing of Neuroblastoma Cells.

Shiffer E, Oyer J, Copik A, Parks G Viruses. 2024; 16(8).

PMID: 39205244 PMC: 11359056. DOI: 10.3390/v16081270.

References

Ferrucci P, Pala L, Conforti F, Cocorocchio E . Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma. Cancers (Basel). 2021; 13(6). PMC: 8003308. DOI: 10.3390/cancers13061383. View

Todo T, Ito H, Ino Y, Ohtsu H, Ota Y, Shibahara J . Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial. Nat Med. 2022; 28(8):1630-1639. PMC: 9388376. DOI: 10.1038/s41591-022-01897-x. View

Qiao Q, Song M, Song C, Zhang Y, Wang X, Huang Q . Single-Dose Vaccination of Recombinant Chimeric Newcastle Disease Virus (NDV) LaSota Vaccine Strain Expressing Infectious Bursal Disease Virus (IBDV) VP2 Gene Provides Full Protection against Genotype VII NDV and IBDV Challenge. Vaccines (Basel). 2021; 9(12). PMC: 8704353. DOI: 10.3390/vaccines9121483. View

Vijayakumar G, Palese P, Goff P . Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma. EBioMedicine. 2019; 49:96-105. PMC: 6945240. DOI: 10.1016/j.ebiom.2019.10.032. View

Huang Z, Liu M, Huang Y . Oncolytic therapy and gene therapy for cancer: recent advances in antitumor effects of Newcastle disease virus. Discov Med. 2020; 30(159):39-48. View

Keshavarz M, Mozaffari Nejad A, Esghaei M, Bokharaei-Salim F, Dianat-Moghadam H, Keyvani H . Oncolytic Newcastle disease virus reduces growth of cervical cancer cell by inducing apoptosis. Saudi J Biol Sci. 2020; 27(1):47-52. PMC: 6933251. DOI: 10.1016/j.sjbs.2019.04.015. View

Jiffry J, Thavornwatanayong T, Rao D, Fogel E, Saytoo D, Nahata R . Oncolytic Reovirus (pelareorep) Induces Autophagy in KRAS-mutated Colorectal Cancer. Clin Cancer Res. 2020; 27(3):865-876. PMC: 8130598. DOI: 10.1158/1078-0432.CCR-20-2385. View

Kennedy B, Murphy J, Clements D, Konda P, Holay N, Kim Y . Inhibition of Pyruvate Dehydrogenase Kinase Enhances the Antitumor Efficacy of Oncolytic Reovirus. Cancer Res. 2019; 79(15):3824-3836. DOI: 10.1158/0008-5472.CAN-18-2414. View

Gebremeskel S, Nelson A, Walker B, Oliphant T, Lobert L, Mahoney D . Natural killer T cell immunotherapy combined with oncolytic vesicular stomatitis virus or reovirus treatments differentially increases survival in mouse models of ovarian and breast cancer metastasis. J Immunother Cancer. 2021; 9(3). PMC: 7970295. DOI: 10.1136/jitc-2020-002096. View

10.

Abudoureyimu M, Lai Y, Tian C, Wang T, Wang R, Chu X . Oncolytic Adenovirus-A Nova for Gene-Targeted Oncolytic Viral Therapy in HCC. Front Oncol. 2019; 9:1182. PMC: 6857090. DOI: 10.3389/fonc.2019.01182. View

11.

Mahasa K, de Pillis L, Ouifki R, Eladdadi A, Maini P, Yoon A . Mesenchymal stem cells used as carrier cells of oncolytic adenovirus results in enhanced oncolytic virotherapy. Sci Rep. 2020; 10(1):425. PMC: 6965634. DOI: 10.1038/s41598-019-57240-x. View

12.

Sato-Dahlman M, LaRocca C, Yanagiba C, Yamamoto M . Adenovirus and Immunotherapy: Advancing Cancer Treatment by Combination. Cancers (Basel). 2020; 12(5). PMC: 7281656. DOI: 10.3390/cancers12051295. View

13.

Matsunaga W, Gotoh A . Adenovirus as a Vector and Oncolytic Virus. Curr Issues Mol Biol. 2023; 45(6):4826-4840. PMC: 10297569. DOI: 10.3390/cimb45060307. View

14.

Zhao Y, Liu Z, Li L, Wu J, Zhang H, Zhang H . Oncolytic Adenovirus: Prospects for Cancer Immunotherapy. Front Microbiol. 2021; 12:707290. PMC: 8334181. DOI: 10.3389/fmicb.2021.707290. View

15.

Blanchette P, Teodoro J . A Renaissance for Oncolytic Adenoviruses?. Viruses. 2023; 15(2). PMC: 9964350. DOI: 10.3390/v15020358. View

16.

Cook J, Peng K, Witzig T, Broski S, Villasboas J, Paludo J . Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma. Blood Adv. 2022; 6(11):3268-3279. PMC: 9198941. DOI: 10.1182/bloodadvances.2021006631. View

17.

Hastie E, Grdzelishvili V . Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer. J Gen Virol. 2012; 93(Pt 12):2529-2545. PMC: 4091291. DOI: 10.1099/vir.0.046672-0. View

18.

Felt S, Grdzelishvili V . Recent advances in vesicular stomatitis virus-based oncolytic virotherapy: a 5-year update. J Gen Virol. 2017; 98(12):2895-2911. PMC: 5845697. DOI: 10.1099/jgv.0.000980. View

19.

Barber G . Vesicular stomatitis virus as an oncolytic vector. Viral Immunol. 2005; 17(4):516-27. DOI: 10.1089/vim.2004.17.516. View

20.

Diaz R, Galivo F, Kottke T, Wongthida P, Qiao J, Thompson J . Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Res. 2007; 67(6):2840-8. DOI: 10.1158/0008-5472.CAN-06-3974. View